Affordable Access

Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation.

Authors
  • Devine, S M
  • Newman, N J
  • Siegel, J L
  • Joseph, G J
  • Geis, T C
  • Schneider, J A
  • Geller, R B
  • Wingard, J R
Type
Published Article
Journal
Bone Marrow Transplantation
Publisher
Springer Nature
Publication Date
Sep 01, 1996
Volume
18
Issue
3
Pages
569–572
Identifiers
PMID: 8879619
Source
Medline
License
Unknown

Abstract

Three patients who developed acute onset of cerebral blindness within 5-47 days of BMT using tacrolimus (FK506) as primary GVHD prophylaxis are described. This syndrome has been described with the use of cyclosporin A (CsA) and FK506 in solid organ transplant recipients. CsA-induced cerebral blindness has also been noted in BMT recipients but to date there have been no reports of this complication in BMT patients receiving FK506. We have noted a striking similarity in the clinical and radiographic presentations between these patients and those with CsA-associated cerebral blindness. Reversibility within 1-2 weeks of onset and the potential for substitution of CsA for FK506 in these patients is described.

Report this publication

Statistics

Seen <100 times